Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 4,54 € (-19,93 %). Medianen er 4,54 € (-19,93 %).
| Køb |
0 |
| Behold |
2 |
| Sælg |
2 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Embecta exceeds Q3 expectations and raises full-year outlook
Embecta reported adjusted EPS of $0.56 and revenue of $271.7 million for Q3 2026, significantly beating consensus estimates. The company raised its forecasts for adjusted operating margin to 23.5–24% and adjusted EPS to $1.80–1.90, but left its 2026 revenue guidance unchanged. Despite a year‑over‑year revenue decline, Embecta benefited from cost cuts, the contribution from the acquisition of Owen Mumford and a sequential improvement in results; however, the U.S. business remains under pressure. » Mere på de.investing.com
Embecta resets U.S. outlook after retailer share loss and pushes GLP-1, Owen Mumford diversification
Embecta cut its U.S. guidance after a challenging quarter marked by loss of shelf position at a major retailer—attributed mainly to price pressure—softer insulin pen prescriptions and inventory adjustments. CEO Devdatt Kurdikar said the company is assessing whether the weakness is temporary or structural amid rising GLP-1 affordability and insurance changes. Embecta is accelerating diversification via lower‑priced pen needles and syringes, a GLP‑1 B2B channel and the pending Owen Mumford acquisition while targeting about $100 million in free cash flow and prioritizing debt reduction and buybacks. » Mere på finance.yahoo.com
S&P downgrades Embecta to B after sales decline in pen needles
S&P Global Ratings cut Embecta’s rating from B+ to B with a stable outlook after second fiscal quarter sales fell 14%. Reasons cited include roughly 20% currency‑adjusted revenue weakness in insulin pen needles, market share losses to a lower‑priced competitor, and weaker US market demand (lower insulin usage, a shift to cheaper channels, increased use of automated systems and GLP‑1 drugs). S&P expects about a 6% sales decline in 2026, an adjusted margin down roughly 800 basis points to 29%, and leverage of 4.5–5x; the acquisition of Owen Mumford is expected to be financed via the revolving credit facility and the dividend will be cut to reduce debt. » Mere på de.investing.com
Embecta misses Q2 2026 forecasts significantly, stock falls 44% premarket
Embecta reported Q2 2026 EPS of $0.27 versus $0.42 expected and revenue of $221.8 million versus $235.66 million expected. Revenue fell 14.4% year-on-year, driven by a 29.4% decline in the US business, prompting the company to lower its full-year guidance. The stock plunged in premarket trading from $9.25 to $5.15. Management announced a review of the cost and organizational structure, brand and product initiatives, and the integration of Owen Mumford as a strategic move. » Mere på de.investing.com
Embecta to acquire Owen Mumford for up to £150 million
Embecta has signed a definitive agreement to acquire British medical‑technology manufacturer Owen Mumford. On closing Embecta will pay £100 million in cash plus up to £50 million in contingent payments, depending on net sales of the Aidaptus autoinjector platform in the three years after closing. Owen Mumford recorded net sales of £69.4 million in 2025; the transaction is expected to close in the third quarter of fiscal 2026, subject to regulatory approvals. Embecta expects growth and long‑term accretion from 2027 but foresees a dilution of adjusted net income in 2027; financing will be partly provided through its revolving credit facility. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 238,07 mio. | 5,04 % |
| Bruttofortjeneste | 134,32 mio. | 18,81 % |
| Nettoresultat | 18,49 mio. | 52,11 % |
| EBITDA | 56,69 mio. | 39,58 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 332,62 mio. € |
Antal aktier | 56,66 mio. |
Højeste/laveste i 52 uger | 13,46 € - 2,52 € |
Udbytteafkast | 4,87 % |
Udbytte TTM | 0,28 € |
Beta | 0,81 |
P/E (PE Ratio) | 4,34 |
PEG (PEG Ratio) | 0,88 |
K/I (PB Ratio) | -0,62 |
P/S (PS Ratio) | 0,36 |
Virksomhedsprofil
Embecta Corp., en medicinsk udstyrsvirksomhed, fokuserer på at levere forskellige løsninger, der skal forbedre sundheden og velværet for mennesker med diabetes. Virksomhedens produkter omfatter pennåle, sprøjter og sikkerhedsudstyr samt digitale applikationer, der hjælper mennesker med at håndtere deres diabetes. Virksomheden sælger primært sine produkter til grossister og distributører i USA og internationalt. Embecta Corp. blev grundlagt i 1924 og har hovedsæde i Parsippany, New Jersey. Embecta Corp. (NasdaqGS:EMBC) opererer uafhængigt af Becton, Dickinson and Company fra 1. april 2022.
| Navn | Embecta Aktie |
| CEO | Devdatt Kurdikar |
| Hjemsted | Parsippany,
nj USA |
| Websted | |
| Sektor | Cykliske forbrugsvarer |
| Branche | Forbrugsgoder |
| Børsnotering | 22.03.2022 |
| Medarbejdere | 1.850 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | EMBC |
Frankfurt | JX7.F |
Düsseldorf | JX7.DU |
München | JX7.MU |